Abstract
Benralizumab is a humanized immunoglobulin G1 monoclonal antibody that specifically binds to the alpha interleukin (IL)-5 receptor, blocking the signaling pathway that activates eosinophils. Furthermore, through its constant Fc region, it has the capability to bind to the FCγRIII receptor of natural killer cells and other immune cells, leading to the apoptosis of eosinophils through degranulation of these immune cells. 1 Pelaia C Vatrella A Bruni A Terracciano R Pelaia G Benralizumab in the treatment of severe asthma: design, development and potential place in therapy. Drug Des Dev Ther. 2018; 12: 619-628 Crossref PubMed Scopus (33) Google Scholar Here, we present a case of cytokine-release hypersensitivity reaction (CRHR) induced by benralizumab therapy in a patient with severe eosinophilic asthma.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
